RT Journal Article
SR Electronic
T1 In Vivo Positronium Lifetime Measurements with a Long Axial Field-of-View PET/CT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.19.24315509
DO 10.1101/2024.10.19.24315509
A1 Mercolli, Lorenzo
A1 Steinberger, William M.
A1 Sari, Hasan
A1 Afshar-Oromieh, Ali
A1 Caobelli, Federico
A1 Conti, Maurizio
A1 Felgosa Cardoso, Ângelo R.
A1 Mingels, Clemens
A1 Moskal, Paweł
A1 Pyka, Thomas
A1 Rathod, Narendra
A1 Schepers, Robin
A1 Seifert, Robert
A1 Shi, Kuangyu
A1 Stępień, Ewa Ł.
A1 Viscione, Marco
A1 Rominger, Axel O.
YR 2024
UL http://medrxiv.org/content/early/2024/10/22/2024.10.19.24315509.abstract
AB Purpose: The lifetime of orthopositronium (oPs), a spin triplet of an electron and positron, depends on the molecular structure of the surrounding tissue. Therefore, measuring oPs lifetime could in principle provide diagnostic information about the tissue microenvironment that goes beyond standard positron emission tomography (PET) imaging. This study demonstrates that in vivo oPs lifetime measurement is feasible with a commercial long axial field-of-view (LAFOV) PET/CT scanner. Methods: Three subjects received a dose of 148.8 MBq [68Ga]-Ga-DOTA-TOC, 159.7 MBq [68Ga]Ga-PSMA-617 and 420.7 MBq [82Rb]Cl. In addition to the standard protocol, the three subjects were scanned for 20, 40 and 10 minutes with a single-crystal interaction acquisition mode on a Biograph Vision Quadra (Siemens Healthineers) PET/CT. Three-photon events, that include two anni- hilation photons and a prompt photon from the decay of the radionuclide, are then selected from the list mode data based on energy, time and spatial selection criteria using a prototype software. The spatial location of the annihilation events is reconstructed using the annihilation photons' time-of-flight. Through a Bayesian fit to the measured time difference between the annihilation and the prompt photons, we are able to determine the oPs lifetime for selected organs. The Bayesian fitting methodology is extended to a hierarchical model in order to investigate possible common oPs lifetime distributions of the heart chambers in the [82Rb]Cl scan. Results: From the segmentation of the subjects' histoimages of three-photon events, we present the highest density intervals (HDI) of the oPs lifetime's marginalized posterior distribution for selected organs. Interestingly, the mean values of the right heart chambers were higher than in the left heart chambers of the subject that received [82Rb]Cl: the 68% HDI of the atria are [1.15 ns, 1.72 ns] (left) and [1.46 ns, 1.99 ns] (right) with mean values 1.50 ns and 1.76 ns, respectively. For the ventricles we obtained [1.22 ns, 1.60 ns] (left) and [1.69 ns, 2.18 ns] (right) with mean values 1.44 ns and 1.96 ns. This might signal the different oxygenation levels of venous and arterial blood. Fitting a hierarchical model, we found that the oPs lifetime for volumes-of-interest with arterial blood can be sampled form a posterior distribution with a 68% HDI of [1.4 ns, 1.84 ns] (mean 1.62 ns) and while those containing venous blood have a HDI of [1.78 ns, 2.21 ns] (mean 2.0 ns). Through arterial and venous blood sampling, we were unable to confirm such a difference in the oPs lifetime. Conclusion: In vivo oPs lifetime measurements on a commercial LAFOV PET/CT system are feasible at the organ level with an unprecedented level of statistical power. Nevertheless, count statistics of three-photon events (especially for 68Ga-based measurements) and the interpretation of oPs lifetimes in human tissue remain major challenges that need to be addressed in future studies. Keywords: Positronium, Long axial field-of-view PET/CT, [82Rb]Cl, [68Ga]-PSMA-617, [68Ga]-DOTA-TOCCompeting Interest StatementWMS and MC are full-time employees of Siemens Medical Solutions USA, Inc. HS is a part-time employee of Siemens Healthineers International AG. PM is an inventor on a patent related to this work. Patent nos.: (Poland) PL 227658, (Europe) EP 3039453, and (United States) US 9,851,456], filed (Poland) 30 August 2013, (Europe) 29 August 2014, and (United States) 29 August 2014; published (Poland) 23 January 2018, (Europe) 29 April 2020, and (United States) 26 December 2017. FC is currently supported by a research grant from Siemens Healthineers and receives speaker honoraria from Bracco AG and Pfizer AG for matters not related to the present manuscript. AR has received research support and speaker honoraria from Siemens. KS received research support from Novartis and Siemens and conference sponsorship from United Imaging, Siemens, and Subtle Medical not related to the submitted work. All other authors have no conflict of interests to report.Funding StatementThis research is partially supported by the grant no. 216944 under the Weave/Lead Agency program of the Swiss National Science Foundation and the National Science Centre of Poland through grant OPUS24+LAP No. 2022/47/I/NZ7/03112.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed in line with the principles of the Declaration of Helsinki. The Kantonale Ethikkommission Bern approved the patient acquisitions (KEK-Nr. 2022—00486 and 2020-02903). All patients provided written informed consent for inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesEvaluated data from the 82Rb dataset is available in the Zenodo repository https://doi.org/10.5281/zenodo.11243763. The remaining datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.https://doi.org/10.5281/zenodo.11243763